In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

Sanofi India Q3 Results Live : Sanofi India announced its Q3 results on November 7, 2024, revealing a significant decline in both revenue and profit. The company reported a topline decrease of 26. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The booth of France's largest healthcare company, Sanofi, showcases the innovative treatment Tzield, the world's first and only disease modifying therapy to delay the onset of type 1 diabetes and ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The quest to understand and slow disease progression in ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

Former Democratic congresswoman Tulsi Gabbard has been appointed as the director of national intelligence by US President-elect Donald Trump. Gabbard, who switched to the Republican Party, is a ...

Mom of 3 was brutally tortured before being set ablaze in Manipur: Autopsy A horrifying incident in Manipur's Jiribam district has left the community reeling after a 31-year-old mother of three ...